Effect of renal impairment on the pharmacokinetics of antimony in hamsters

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Tropical Medicine and Parasitology

• Publication date

  2004-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1179/000349804X3171PMID 15667712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of Antimony in Patients Treated with Sodium Stibogluconate for Cutaneous Leishmaniasis

  2004influential reference
• Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis

  2003cited by this paper
• Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major.

  2002cited by this paper
• Management of cutaneous leishmaniasis

  2001cited by this paper
• Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial.

  2001cited by this paper
• Temporary warm ischaemia, 5/6 nephrectomy and single uranyl nitrate administration--comparison of three models intended to cause renal fibrosis in rats.

  2001cited by this paper
• Chronic renal failure

  2001cited by this paper
• Antimony Excretion in a Patient with Renal Impairment During Meglumine Antimoniate Therapy

  2000cited by this paper
• High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.

  1999cited by this paper
• [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis].

  1997cited by this paper
• Renal dysfunction in patients of kala azar treated with sodium antimony gluconate.

  1994cited by this paper
• Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine.

  1994cited by this paper
• The treatment of kala-azar in the Sudan with sodium stibogluconate: a randomized trial of three dosage regimens.

  1993cited by this paper
• Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds.

  1993cited by this paper
• Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol.

  1992cited by this paper
• Pentavalent antimonial nephrotoxicity in the rat.

  1990cited by this paper
• Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.

  1988cited by this paper
• Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters.

  1988cited by this paper
• Renal tubular dysfunction in patients with mucocutaneous leishmaniasis treated with pentavalent antimonials.

  1983cited by this paper
• Pharmacokinetics, Second Edition

  1982cited by this paper
• Renal clearance of pentavalent antimony (sodium stibogluconate).

  1980cited by this paper
• The leishmaniases.

  1974cited by this paper
• Acute Renal Failure

  1960cited by this paper

• Tetranuclear and dinuclear Cu(II) complexes with risedronate as anti-Trypanosoma cruzi and anti-Leishmania mexicana agents. Synthesis, crystal structures, and biological evaluation.

  2025cites this paper
• Medicinal Rhodiola imbricata induces protective immune responses against susceptible and resistant strains of Leishmania donovani in murine model

  2024cites this paper
• An Overview on Leishmaniasis in Romania: Diagnosis and Therapeutics

  2022cites this paper
• Leishmaniasis: where are we and where are we heading?

  2021cites this paper
• A RESISTÊNCIA AOS ANTIMONIAIS PODE LEVAR AO AUMENTO DA VIRULÊNCIA EM LEISHMANIA SPP.?

  2020cites this paper
• Metal Compounds against Neglected Tropical Diseases.

  2018cites this paper
• Histological Study on the effect of Miltefosine in treatingVisceral Leishmaniasis

  2017cites this paper
• Liposomal formulations in the pharmacological treatment of leishmaniasis: a review

  2017cites this paper
• Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis.

  2016cites this paper
• Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis

  2016cites this paper
• Anti-Leishmanial Activity (In Vitro and In Vivo) of Allicin and Allicin Cream Using Leishmania major (Sub-strain Zymowme LON4) and Balb/c Mice

  2016cites this paper
• Oleanolic acid loaded poly lactic co- glycolic acid- vitamin E TPGS nanoparticles for the treatment of Leishmania donovani infected visceral leishmaniasis.

  2016cites this paper
• Treatment of leishmaniasis: a review and assessment of recent research.

  2015cites this paper
• Epidemiological studies on zoonotic leishmaniasis and new trials for studying the effect of melatonin on the parasite

  2015cites this paper
• Therapeutic Arsenal against Leishmaniases: A Review

  2015cites this paper
• Leishmaniasis: History, Evolution of Treatment and the Need for New Drugs

  2015cites this paper
• Antileishmanial drug discovery: comprehensive review of the last 10 years

  2015cites this paper
• The influence of treatment on the development of leishmaniasis recidiva cutis: a 17‐year case–control study in Midwestern Brazil

  2015cites this paper
• New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape

  2015cites this paper
• Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease

  2014cites this paper
• Management of canine leishmaniosis in endemic SW European regions: a questionnaire-based multinational survey

  2014cites this paper
• AVALIAÇÃO DA ATIVIDADE LEISHMANICIDA DO ANTIMÔNIO TRIVALENTE LIVRE OU EM FORMULAÇÃO LIPOSSOMAL CONVENCIONAL, ASSOCIADO OU NÃO AO ÁCIDO ASCÓRBICO, EM CAMUNDONGOS BALB/c INFECTADOS COM LEISHMANIA INFANTUM.

  2013cites this paper
• Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?

  2012cites this paper
• Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis.

  2009cites this paper
• Effects of fluconazole on the pharmacokinetics and pharmacodynamics of antimony in cutaneous leishmaniasis-infected hamsters.

  2007cites this paper